Palvella Therapeutics (PVLA) Competitors $71.30 -2.02 (-2.76%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PVLA vs. QURE, GMTX, XENE, SRRK, RARE, AMRX, IMVT, CNTA, TARS, and APLSShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include uniQure (QURE), Gemini Therapeutics (GMTX), Xenon Pharmaceuticals (XENE), Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), Amneal Pharmaceuticals (AMRX), Immunovant (IMVT), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Its Competitors uniQure Gemini Therapeutics Xenon Pharmaceuticals Scholar Rock Ultragenyx Pharmaceutical Amneal Pharmaceuticals Immunovant Centessa Pharmaceuticals Tarsus Pharmaceuticals Apellis Pharmaceuticals uniQure (NASDAQ:QURE) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Do institutionals and insiders hold more shares of QURE or PVLA? 78.8% of uniQure shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is QURE or PVLA more profitable? Palvella Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. Palvella Therapeutics' return on equity of -62.30% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-1,387.98% -1,010.74% -33.27% Palvella Therapeutics N/A -62.30%-43.34% Which has preferable earnings & valuation, QURE or PVLA? Palvella Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$27.12M120.04-$239.56M-$3.92-15.14Palvella Therapeutics$42.81M18.42-$17.43M-$12.10-5.89 Does the media favor QURE or PVLA? In the previous week, Palvella Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Palvella Therapeutics and 0 mentions for uniQure. Palvella Therapeutics' average media sentiment score of 0.24 beat uniQure's score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral Palvella Therapeutics Neutral Which has more risk and volatility, QURE or PVLA? uniQure has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Do analysts rate QURE or PVLA? uniQure currently has a consensus target price of $71.75, suggesting a potential upside of 20.93%. Palvella Therapeutics has a consensus target price of $75.50, suggesting a potential upside of 5.89%. Given uniQure's higher probable upside, research analysts clearly believe uniQure is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Palvella Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92 SummaryPalvella Therapeutics beats uniQure on 9 of the 15 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$810.90M$3.44B$6.19B$10.60BDividend YieldN/A2.26%5.72%4.86%P/E RatioN/A8.2221.1124.06Price / Sales18.42477.59577.46128.87Price / CashN/A44.5736.5560.64Price / Book12.7810.3512.076.53Net Income-$17.43M-$52.53M$3.32B$276.75M7 Day Performance-2.52%-0.22%-0.16%0.20%1 Month Performance25.77%10.89%5.76%1.67%1 Year PerformanceN/A14.19%65.71%32.73% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics1.6401 of 5 stars$71.30-2.8%$75.50+5.9%N/A$810.90M$42.81M0.00N/AShort Interest ↑QUREuniQure2.6033 of 5 stars$62.83+6.6%$71.75+14.2%+800.9%$3.23B$27.12M-16.03500GMTXGemini TherapeuticsN/A$73.00+1.4%N/A+69.2%$3.16BN/A-73.0030XENEXenon Pharmaceuticals2.7067 of 5 stars$41.90+3.3%$53.67+28.1%-1.3%$3.13B$7.50M-11.80210SRRKScholar Rock4.4218 of 5 stars$32.40+1.6%$48.60+50.0%-2.0%$3.07B$33.19M-11.13140Analyst ForecastGap DownRAREUltragenyx Pharmaceutical4.3238 of 5 stars$33.43+5.5%$81.50+143.8%-39.5%$3.05B$610.16M-6.051,294Analyst ForecastGap UpAMRXAmneal Pharmaceuticals2.566 of 5 stars$9.78+0.6%$12.00+22.7%+22.7%$3.05B$2.85B978.988,100IMVTImmunovant2.2687 of 5 stars$17.93+2.5%$28.78+60.5%-36.1%$3.05BN/A-6.29120CNTACentessa Pharmaceuticals3.6075 of 5 stars$22.57+0.7%$32.38+43.4%+50.6%$3.00B$6.85M-12.61200TARSTarsus Pharmaceuticals1.5324 of 5 stars$74.95+7.3%$66.67-11.1%+80.8%$2.95B$182.95M-32.1750Analyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.0481 of 5 stars$25.22+8.9%$33.47+32.7%+2.0%$2.92B$781.37M-13.86770Upcoming EarningsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies QURE Competitors GMTX Competitors XENE Competitors SRRK Competitors RARE Competitors AMRX Competitors IMVT Competitors CNTA Competitors TARS Competitors APLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVLA Stock Alerts